UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2007-07, Vol.25 (21), p.3109-3115

2007

Volltextzugriff (PDF)

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

PloS one, 2015-08, Vol.10 (8), p.e0135945-e0135945

2015

Volltextzugriff (PDF)

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

Journal of clinical oncology, 2001-09, Vol.19 (18), p.3852-3860

2001

Volltextzugriff (PDF)

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

Journal of clinical oncology, 2005-01, Vol.23 (3), p.474-481

2005

Volltextzugriff (PDF)

Targeting T cells to tumor cells using bispecific antibodies

Current opinion in chemical biology, 2013-06, Vol.17 (3), p.385-392

2013

Volltextzugriff (PDF)

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4110-4116

2005

Volltextzugriff (PDF)

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3854-3861

2005

Volltextzugriff (PDF)

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

Clinical cancer research, 2006-12, Vol.12 (23), p.7039-7045

2006

Volltextzugriff (PDF)

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Blood, 2014-01, Vol.123 (4), p.554-561

2014

Volltextzugriff (PDF)

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Blood, 2007-01, Vol.109 (1), p.31-39

2007

Volltextzugriff (PDF)

Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Seminars in oncology, 2003-04, Vol.30 (2), p.121-126

2003

Volltextzugriff (PDF)

Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2003-04, Vol.21 (7), p.1278-1284

2003

Volltextzugriff (PDF)

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Blood, 2009-04, Vol.113 (16), p.3673-3678

2009

Volltextzugriff (PDF)

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (10), p.3785-3794

2008

Volltextzugriff (PDF)

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Blood, 2007-05, Vol.109 (10), p.4164-4167

2007

Volltextzugriff (PDF)

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza(TM), suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Investigational new drugs, 2008-02, Vol.26 (1), p.81

2008

Volltextzugriff (PDF)

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Investigational new drugs, 2008-02, Vol.26 (1), p.81-87

2008

Volltextzugriff (PDF)

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

Leukemia & lymphoma, 2012-08, Vol.53 (8), p.1501-1508

2012

Volltextzugriff (PDF)

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis

Seminars in oncology, 2003-04, Vol.30 (2), p.300-304

Frankel, Stanley R.

2003

Volltextzugriff (PDF)

Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer

Clinical cancer research, 2004-06, Vol.10 (12), p.4245s-4248s

2004

Volltextzugriff (PDF)

Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature

American journal of hematology, 2002-08, Vol.70 (4), p.320-323

2002

Volltextzugriff (PDF)

The "retinoic acid syndrome" in acute promyelocytic leukemia

Annals of internal medicine, 1992-08, Vol.117 (4), p.292-296

1992

Volltextzugriff (PDF)

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

The New England journal of medicine, 1991-05, Vol.324 (20), p.1385-1393

1991

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(96)

Erscheinungsjahr

n.n

Thema

Humans
(59)
Science & Technology
(57)
Life Sciences & Biomedicine
(52)
Biological And Medical Sciences
(38)
Medical Sciences
(37)
Middle Aged
(31)
Adult
(30)
Male
(29)
Oncology
(29)
Aged
(28)
Female
(27)
Hematology
(22)
Pharmacology. Drug Treatments
(19)
Antineoplastic Agents
(16)
Treatment Outcome
(16)
Adolescent
(15)
Chemotherapy
(15)
Remission Induction
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Aged, 80 And Over
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

Targeting T cells to tumor cells using bispecific antibodies

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza(TM), suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer

Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature

The "retinoic acid syndrome" in acute promyelocytic leukemia

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

Suchergebnisse filtern